IDEXX Laboratories (IDXX) is back in focus after unveiling new veterinary diagnostic products, including the ImageVue DR50 Plus imaging system and expanded Cancer Dx Panel, developments that may influence how investors view its long term growth profile.

The share price has been choppy in the short term, with a 7 day share price return of a 3.01% decline and a modest 30 day gain of 0.82%. However, the 1 year total shareholder return of 59.38% and 3 year total shareholder return of 42.47% indicate momentum that has been stronger over longer horizons, as recent product launches and the planned CEO transition keep attention on how the story might evolve.

If these veterinary diagnostics launches have you thinking more broadly about healthcare, it could be a good moment to scan other opportunities across healthcare stocks.

With IDEXX trading at US$693.85 and sitting around 10% below the average analyst price target, while also screening as expensive on some intrinsic metrics, you have to ask: is there still upside here, or is future growth already priced in?

Most Popular Narrative: 8.1% Undervalued

At $693.85, IDEXX Laboratories is trading below a widely followed fair value estimate of $754.83, which rests on detailed forecasts for growth, margins, and future earnings multiples.

Rapid adoption of innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand, which is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.

Curious what kind of revenue trajectory, margin lift, and future P/E this story assumes to reach that fair value? The narrative leans on a tight set of forecasts that may surprise you.

Result: Fair Value of $754.83 (UNDERVALUED)

However, that upbeat story still leans heavily on continued double digit international diagnostics growth and robust instrument placements, both of which could disappoint if adoption slows.

Another View: High Price Tag On Earnings

While the fair value narrative points to an 8.1% discount, IDEXX currently trades on a P/E of 53.9x, compared with 32x for the US Medical Equipment industry, 28.1x for peers, and a fair ratio of 30.3x. That kind of gap raises a simple question: how much future perfection is already in the price?

Build Your Own IDEXX Laboratories Narrative

If you look at the numbers and come to a different conclusion, or simply prefer to trust your own work, you can build a custom IDEXX view in minutes with Do it your way.

A great starting point for your IDEXX Laboratories research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If IDEXX has sharpened your thinking, do not stop here. Use the Simply Wall St Screener to uncover fresh ideas that could better fit your goals.

• Spot potential bargains early by scanning these 864 undervalued stocks based on cash flows that screen well on cash flow based metrics and may warrant a closer look.
• Ride powerful technology themes by focusing on these 24 AI penny stocks that connect artificial intelligence with real business models and measurable fundamentals.
• Lock in potential income streams by reviewing these 13 dividend stocks with yields > 3% that combine higher yields with underlying business data you can inspect in detail.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.